SLC2A1 and breast cancer: Multiple studies have reported GLUT1 upregulation owing to mutations in HIF‐1α, RAS, p53, and the PI3K/AKT signaling pathway in breast cancer (BC), esophageal cancer (EC), pancreatic cancer, and colorectal cancer (CRC).